Clinical Report: Dysfunction of the Skin Barrier and Psoriasis Development

Background

Psoriasis is a prevalent chronic inflammatory autoimmune skin disease affecting 0.1% to 3% of the global population. The skin barrier is essential for maintaining homeostasis and protecting against external insults, and its dysfunction is increasingly recognized as a significant factor in psoriasis pathogenesis. Understanding the interplay between skin barrier integrity and psoriasis is crucial for developing effective therapeutic strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

• Skin barrier dysfunction is an early and pivotal driver of psoriasis.
• Mechanisms of barrier impairment include keratinocyte hyperproliferation and tight junction disruption.
• Aberrant expression of structural proteins and aquaporin 3 dysfunction are implicated in psoriasis pathogenesis.
• Research gaps exist regarding the molecular mechanisms linking skin barrier dysfunction and psoriasis.

Clinical Implications

Clinicians should consider the role of skin barrier dysfunction in the management of psoriasis, particularly in patients with treatment-resistant lesions.

Conclusion

Elucidating the relationship between skin barrier dysfunction and psoriasis is essential.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse
2. conexiant, 2026 -- UVB and Psoriasis: More Than Immunosuppression
3. Frontiers in Pediatrics, 2026 -- The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment
4. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris | EDFG
5. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial - PubMed
6. JMIR Dermatology — Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes
7. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris | EDFG
8. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial - PubMed
9. https://www.nature.com/articles/s41598-025-12111-6.pdf